About Carus Laboratories Private Limited
Data last updated: 06 January 2026
Carus Laboratories Private Limited is a private limited company based in Delhi, Delhi, India. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 30 December 2005, the company has been in operation for over 21 years.
Registered with ROC Delhi under CIN U24231DL2005PTC144250.
Capital: an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Jitender Pal Pilani and Krishna Devi.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2024. Office: 164 Pocket 24 Sector 24Rohini Delhi Rohini Delhi, Delhi, India.
As per the financials filed for FY 2025, the company reported a revenue of ₹128.85 Cr, a growth of 24% compared to the previous year.
The company has a workforce of approximately 579 employees as per the latest available data.
The company is associated with 1 brand - Carus Laboratories. As per MCA filings, the company has satisfied charges of ₹30 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website caruslab.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address164 Pocket 24 Sector 24Rohini Delhi Rohini Delhi, Delhi, India
-
IndustryPharma, Animal Pharmaceuticals & Healthcare
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Carus Laboratories Private Limited
Carus Laboratories Private Limited operates one associated brand: Carus Laboratories. These brands represent Carus Laboratories Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides comprehensive solutions for veterinary feed supplements. | caruslab.com |
Competitors & Alternatives of Carus Laboratories Private Limited
Brands and companies operating in the same space as Carus Laboratories Private Limited include Zoetis, Ceva, QBiotics and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Zoetis
|
Animal medicines, vaccines, and diagnostics are manufactured and supplied. | Brussels, Belgium, Belgium | 2012 |
Ceva
|
Animal health therapeutics are developed and supplied globally by Ceva. | Libourne, France, France | 1999 |
QBiotics
|
Small molecules from plant extracts are developed for medical applications. | Brisbane, Australia, Australia | 2000 |
PetMedix
|
Developer of monoclonal antibody therapeutics for pets | Babraham, United Kingdom, United Kingdom | 2017 |
Hester Biosciences
|
Manufacturer of animal vaccines and healthcare products | Ahmedabad, India, India | 1987 |
Bio-Sourcing
|
Biopharmaceuticals for animals are manufactured and supplied through partnerships. | Liege, Belgium, Belgium | 2014 |
KindredBio
|
Veterinary antibodies for cats, dogs, and horses are developed. | Burlingame, United States, United States | 2012 |
The Vaccine Group
|
Herpesvirus-based animal vaccines are developed against infectious diseases. | Plymouth, United Kingdom, United Kingdom | 2017 |
Weijiexin Biological Technology
|
Protein-based biopharmaceuticals for animal disease treatment are developed. | Haidian, China, China | 2016 |
Peptobiotics
|
Peptides-based livestock feed additives are manufactured for animal nutrition. | Singapore, Singapore, Singapore | 2021 |
Business Activity of Carus Laboratories Private Limited
Carus Laboratories Private Limited is engaged in the principal business activity of trade, with detailed activities including retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | ********* |
Auditor Details of Carus Laboratories Private Limited
Carus Laboratories Private Limited is audited by HARJINDER SINGH AND CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| HARJINDER SINGH AND CO. | blur-value | blur-value | blur-value |
Board of Directors of Carus Laboratories Private Limited
Carus Laboratories Private Limited is governed by 3 directors who oversee the company's operations and strategic decisions.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jitender Pal Pilani | Director | 30 Dec 2005 | 20 Years 6 Months | Current |
| Krishna Devi | Director | 30 Dec 2005 | 20 Years 6 Months | Current |
| Arun Pilani | Director | 05 Jul 2012 | 14 Years 0 Months | Current |
Financials of Carus Laboratories Private Limited FY 2024 filings available
Carus Laboratories Private Limited reported revenue of ₹128.85 Cr (up 24% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Carus Laboratories Private Limited
As of FY 2023, Carus Laboratories Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Carus Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jun 2011 | Punjab National Bamk | ₹30 Lakh | Satisfied |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Carus Laboratories Private Limited
Carus Laboratories Private Limited has a workforce of 579 employees as of Apr 04, 2024.
Employee Count & EPFO Data of Carus Laboratories Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Carus Laboratories Private Limited
GSTIN & GST Filing Data of Carus Laboratories Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Carus Laboratories Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Carus Laboratories Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Carus Laboratories Private Limited
MSME Payment Delays by Carus Laboratories Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Carus Laboratories Private Limited
Subsidiaries & Group Companies of Carus Laboratories Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Carus Laboratories Private Limited with ownership details.
MCA Filings & Documents of Carus Laboratories Private Limited
MCA Filings & Documents of Carus Laboratories Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Carus Laboratories Private Limited
Frequently Asked Questions about Carus Laboratories Private Limited
Carus Laboratories Private Limited is an active private limited company in the pharma sector based in Delhi, Delhi, India. It was incorporated on 30 December 2005 (21+ years old) and is registered under CIN U24231DL2005PTC144250. The company has 579 employees.
Carus Laboratories Private Limited reported revenue of ₹128.85 Cr for FY 2025 (up 24.00% YoY).
The current directors of Carus Laboratories Private Limited are:
The primary industry of Carus Laboratories Private Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.
Carus Laboratories Private Limited can be reached at the registered office: 164 Pocket 24 Sector 24Rohini Delhi Rohini Delhi, Delhi, India, or through the website caruslab.com.
The authorised capital is ₹1 Cr, and the paid-up capital is ₹1 Cr.